中国临床药理学杂志2024，Vol.40Issue(10)：1520-1524,5.DOI:10.13699/j.cnki.1001-6821.2024.10.027
BTK抑制药在B细胞淋巴瘤中的用药模式与治疗费用分析
Analysis of the utilization patterns and costs of BTK inhibitors in B-cell lymphoma
摘要
Abstract
Objective To elucidate utilization patterns,cost and safety of Bruton's tyrosine kinase inhibitors(BTKi)in the real world.Methods A retrospective cohort was designed and constructed using real-world BTKi data from a single lymphoma center.Descriptive analysis was performed to describe the demographic and clinical characteristics of the population.Medicine utilization and cost were quantified by defined daily doses(DDDs)and defined daily dose cost(DDDc),respectively.A generalized estimating equation(GEE)was used to explore the potential influencing factors of platelet aggregation rate(PAR).Results The study cohort included 193 patients[median age,65 years;77(39.90％)women],most of whom received ibrutinib(n=109,56.48％),and 77.20％patients combined BTKi with chemotherapy or targeted therapy.The implementation of national negotiation policy had a large impact on medicine utilization and cost.The DDDs difference between the two BTKis was reduced from 18.55 to 1.41 times.The DDDc for ibrutinib decreased from 1 619.99 Yuan to 567.00 Yuan,and that for zanubrutinib from 706.25 Yuan to 340.00 Yuan was already lower than ibrutinib.Interruptions were more readily observed in patients treated with ibrutinib,and hematological toxicity was the main adverse drug event(ADE)leading to treatment interruption.Besides,the GEE model showed that combining BTKi with antiplatelet medication significantly decreases the PAR[β=-34.35％,95％confidence interval(CI):-41.60％--27.11％,P＜0.001].Compared to zanubrutinib,ibrutinib also notably reduces the PAR(β=-12.38％,95％CI:-24.50％--0.27％,P＜0.05).Conclusion After the implementation of national negotiation policy,there is no significant difference in the clinical preference for two BTKis.Compared with ibrutinib,zanubrutinib showed an advantage in terms of economic profile,treatment interruptions caused by ADE,and the effect on PAR.关键词
伊布替尼/泽布替尼/布鲁顿酪氨酸激酶抑制药/用药模式/治疗费用/治疗中断Key words
ibrutinib/zanubrutinib/Bruton's tyrosine kinase inhibitor/utilization pattern/cost/treatment interruption分类
医药卫生引用本文复制引用
姜丹,宋再伟,胡杨,董菲,赵荣生..BTK抑制药在B细胞淋巴瘤中的用药模式与治疗费用分析[J].中国临床药理学杂志,2024,40(10):1520-1524,5.基金项目
国家自然科学基金资助项目(72074005,72304007) （72074005,72304007）
国家临床重点专科建设基金资助项目(2023) （2023）
